This HTML5 document contains 131 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
dbpedia-shhttp://sh.dbpedia.org/resource/
dctermshttp://purl.org/dc/terms/
yago-reshttp://yago-knowledge.org/resource/
dbohttp://dbpedia.org/ontology/
foafhttp://xmlns.com/foaf/0.1/
n16https://global.dbpedia.org/id/
yagohttp://dbpedia.org/class/yago/
n8http://dbpedia.org/resource/List_of_drugs:
dbthttp://dbpedia.org/resource/Template:
rdfshttp://www.w3.org/2000/01/rdf-schema#
n26http://www.ontologydesignpatterns.org/ont/dul/DUL.owl#
n21http://oncozine.com/page/
dbpedia-srhttp://sr.dbpedia.org/resource/
freebasehttp://rdf.freebase.com/ns/
n17http://
n10http://commons.wikimedia.org/wiki/Special:FilePath/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
wikipedia-enhttp://en.wikipedia.org/wiki/
dbphttp://dbpedia.org/property/
dbchttp://dbpedia.org/resource/Category:
provhttp://www.w3.org/ns/prov#
xsdhhttp://www.w3.org/2001/XMLSchema#
wikidatahttp://www.wikidata.org/entity/
goldhttp://purl.org/linguistics/gold/
dbrhttp://dbpedia.org/resource/
n7http://www.ema.europa.eu/docs/en_GB/document_library/Orphan_designation/2011/11/

Statements

Subject Item
dbr:Brivanib
dbo:wikiPageWikiLink
dbr:Brivanib_alaninate
dbo:wikiPageRedirects
dbr:Brivanib_alaninate
Subject Item
dbr:Bristol_Myers_Squibb
dbo:wikiPageWikiLink
dbr:Brivanib_alaninate
Subject Item
dbr:Brivanib_alaninate
rdf:type
yago:Cognition100023271 yago:HigherCognitiveProcess105770664 yago:WikicatAminoAcidDerivatives yago:Process105701363 wikidata:Q8386 yago:DerivedFunction106014730 yago:ProblemSolving105796750 yago:Abstraction100002137 yago:Calculation105802185 dbo:ChemicalSubstance n26:ChemicalObject owl:Thing yago:PsychologicalFeature100023100 yago:Thinking105770926 dbo:Drug
rdfs:label
Brivanib alaninate
rdfs:comment
Brivanib alaninate (INN/USAN) also known as BMS-582664 is an investigational, anti-tumorigenic drug for oral administration. The drug is being developed by Bristol-Myers Squibb for the treatment of hepatocellular carcinoma or HCC (also called malignant hepatoma), the most common type of liver cancer. Brivanib is no longer in active development. Brivanib alaninate is a multitargeted tyrosine kinase inhibitor (as is sorafenib).
foaf:depiction
n10:Brivanib_alaninate.svg
dcterms:subject
dbc:Prodrugs dbc:Amino_acid_derivatives dbc:Indole_ethers_at_the_benzene_ring dbc:Experimental_cancer_drugs dbc:Carboxylate_esters dbc:Bristol_Myers_Squibb
dbo:wikiPageID
34793637
dbo:wikiPageRevisionID
1100173024
dbo:wikiPageWikiLink
dbr:5-fluorouracil dbr:Hydroxydaunorubicin dbr:Sorafenib dbr:Cirrhosis dbr:FGFR dbr:Growth_inhibition dbr:Hepatocellular_carcinoma dbr:Adriamycin dbc:Prodrugs dbr:Nexavar dbr:Chemotherapeutic_agents dbr:Hepatitis_C dbr:Angiogenesis dbr:Radiofrequency_ablation dbr:Fibroblast_growth_factor dbr:IFN dbr:VEGF dbr:C-kit dbr:Immunotherapy dbr:Fibroblast_growth_factor_receptor dbr:European_Commission dbc:Amino_acid_derivatives dbr:Hepatitis_B dbr:Orphan_designation dbr:In_vivo dbr:Liver_cancer dbr:Down-regulation dbr:Tyrosine_kinases dbr:Overall_survival dbr:Vascular_endothelial_growth_factor_receptor dbr:Platelet-derived_growth_factor_receptor dbc:Indole_ethers_at_the_benzene_ring dbr:Doxorubicin dbr:Broad-spectrum dbr:Metastases dbr:Cisplatin dbr:VEGFR-1 dbr:VEGFR-2 dbr:Bristol-Myers_Squibb dbr:VEGFR-3 dbr:Tyrosine_kinase_inhibitor dbc:Bristol_Myers_Squibb dbr:VEGFR dbr:Endothelial_cells dbr:VEGFR-2_inhibitor dbc:Carboxylate_esters dbr:International_Nonproprietary_Name dbr:Chemotherapy dbc:Experimental_cancer_drugs
dbo:wikiPageExternalLink
n7:WC500117965.pdf n17:www.oncozine.com n21:brivanib-alaninate
owl:sameAs
yago-res:Brivanib_alaninate n16:4bxd6 freebase:m.0j3ddsy dbpedia-sh:Brivanib_alaninat dbpedia-sr:Brivanib_alaninat wikidata:Q4971701
dbp:wikiPageUsesTemplate
dbt:Main_article dbt:Refimprove dbt:Reflist dbt:Short_description dbt:ClinicalTrialsGov dbt:Cn dbt:Drugbox dbt:Fdacite
dbo:thumbnail
n10:Brivanib_alaninate.svg?width=300
dbp:atcPrefix
none
dbp:c
22
dbp:casNumber
649735
dbp:chebi
167656
dbp:chembl
270995
dbp:chemspiderid
9330033
dbp:f
1
dbp:h
24
dbp:iupacName
--1-propan-2-yl 2-aminopropanoate
dbp:legalUs
IND
dbp:n
5
dbp:o
4
dbp:pubchem
11154925
dbp:routesOfAdministration
Oral
dbp:smiles
CC1=CC2=CC=CCOC3=NC=NN4C3=CC
dbp:stdinchi
1
dbp:stdinchikey
LTEJRLHKIYCEOX-OCCSQVGLSA-N
dbp:unii
U2Y5OFN795
dbo:abstract
Brivanib alaninate (INN/USAN) also known as BMS-582664 is an investigational, anti-tumorigenic drug for oral administration. The drug is being developed by Bristol-Myers Squibb for the treatment of hepatocellular carcinoma or HCC (also called malignant hepatoma), the most common type of liver cancer. Brivanib is no longer in active development. Brivanib alaninate is a multitargeted tyrosine kinase inhibitor (as is sorafenib). Brivanib alaninate also inhibits VEGFR and fibroblast growth factor receptors (FGFR), which is known to play a major role in the etiopathogenesis of HCC. To date, brivanib alaninate has been investigated in 29 studies, including more than 4,000 patients around the world.
dbp:iupharLigand
8097
gold:hypernym
dbr:Drug
prov:wasDerivedFrom
wikipedia-en:Brivanib_alaninate?oldid=1100173024&ns=0
dbo:wikiPageLength
11987
dbo:casNumber
649735-63-7
dbo:chEBI
167656
dbo:chEMBL
270995
dbo:fdaUniiCode
U2Y5OFN795
dbo:pubchem
11154925
foaf:isPrimaryTopicOf
wikipedia-en:Brivanib_alaninate
Subject Item
dbr:C22H24FN5O4
dbo:wikiPageWikiLink
dbr:Brivanib_alaninate
dbo:wikiPageRedirects
dbr:Brivanib_alaninate
Subject Item
n8:_Br
dbo:wikiPageWikiLink
dbr:Brivanib_alaninate
Subject Item
dbr:BMS-582664
dbo:wikiPageWikiLink
dbr:Brivanib_alaninate
dbo:wikiPageRedirects
dbr:Brivanib_alaninate
Subject Item
wikipedia-en:Brivanib_alaninate
foaf:primaryTopic
dbr:Brivanib_alaninate